article

Expert view: The path to the high-hanging fruit: access to greater diversity and rapid down-selection

0
SHARES
Share via

Posted: 24 March 2020 | | No comments yet

Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.

As we turn to more difficult targets, such as G-protein coupled receptors (GPCRs) and ion channels, two capabilities are crucial for success: access to greater antibody diversity and the ability to rapidly identify functional lead candidates. The Opto Plasma B Discovery 2.0 Workflow addresses both of these needs by providing access to broad B cell diversity and rapid down-selection of leads in an automated workflow run on the Beacon® platform.











To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Gilson

Related organisations

Send this to a friend